WEGOVY Drug Patent Profile

Which patents cover Wegovy, and what generic alternatives are available?

Wegovy is a drug marketed by Novo and is included in two NDAs. There are fifteen patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and ninety-nine patent family members in thirty-seven countries.

The generic ingredient in WEGOVY is semaglutide. Two suppliers are listed for this compound. Additional details are available on the semaglutide profile page.

DrugPatentWatch^® Generic Entry Outlook for Wegovy

Wegovy was eligible for patent challenges on December 5, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 5, 2031. This may change due to patent challenges or generic licensing.

There have been eighteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for WEGOVY

International Patents:	299
US Patents:	15
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	16
Clinical Trials:	28
Patent Applications:	1,408
Drug Prices:	Drug price information for WEGOVY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for WEGOVY
What excipients (inactive ingredients) are in WEGOVY?	WEGOVY excipients list
DailyMed Link:	WEGOVY at DailyMed

See drug prices for WEGOVY

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for WEGOVY

Constraining patent/regulatory exclusivity:

8,129,343

NDA:

215256

Dosage:

SOLUTION;SUBCUTANEOUS

Constraining patent/regulatory exclusivity:

9,278,123

NDA:

218316

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for WEGOVY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Minnesota	PHASE3
The Metis Foundation	PHASE3
University of Colorado, Denver	PHASE3

See all WEGOVY clinical trials

Pharmacology for WEGOVY

Drug Class	GLP-1 Receptor Agonist
Mechanism of Action	Glucagon-like Peptide-1 (GLP-1) Agonists

Paragraph IV (Patent) Challenges for WEGOVY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
WEGOVY	Injection	semaglutide	0.25 mg/0.5 mL 0.5 mg/0.5 mL 1 mg/0.5 mL 1.7 mg/0.75 mL 2.4 mg/0.75 mL	215256	1	2022-10-20

US Patents and Regulatory Information for WEGOVY

WEGOVY is protected by fifteen US patents and three FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 8,129,343.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novo	WEGOVY	semaglutide	TABLET;ORAL	218316-003	Dec 22, 2025		RX	Yes	No	8,129,343		Y	Y
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-004	Jun 4, 2021		RX	Yes	Yes
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-004	Jun 4, 2021		RX	Yes	Yes	12,214,017		Y
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-005	Jun 4, 2021		RX	Yes	Yes	8,129,343		Y	Y
Novo	WEGOVY	semaglutide	TABLET;ORAL	218316-002	Dec 22, 2025		RX	Yes	No	12,396,953		Y
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-005	Jun 4, 2021		RX	Yes	Yes	11,752,198		Y

Expired US Patents for WEGOVY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novo	WEGOVY	semaglutide	TABLET;ORAL	218316-001	Dec 22, 2025	8,536,122
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-005	Jun 4, 2021	8,536,122
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-001	Jun 4, 2021	8,536,122
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-003	Jun 4, 2021	8,536,122
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-002	Jun 4, 2021	8,536,122
Novo	WEGOVY	semaglutide	TABLET;ORAL	218316-002	Dec 22, 2025	8,536,122

EU/EMA Drug Approvals for WEGOVY

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novo Nordisk A/S	Wegovy	semaglutide	EMEA/H/C/005422Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to	Authorised	no	no	no	2022-01-06
Novo Nordisk A/S	Ozempic	semaglutide	EMEA/H/C/004174Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.	Authorised	no	no	no	2018-02-08
Novo Nordisk A/S	Rybelsus	semaglutide	EMEA/H/C/004953Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin combination with other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.	Authorised	no	no	no	2020-04-03

International Patents for WEGOVY

When does loss-of-exclusivity occur for WEGOVY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

Hungary

Japan

Lithuania

Mexico

Poland

Portugal

Russian Federation

San Marino

Serbia

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering WEGOVY around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2014503526
Brazil	112015026325	dosagem oral de compostos glp-1
Spain	2793423
Taiwan	I847306
Denmark	3326620
Hungary	E066356

Supplementary Protection Certificates for WEGOVY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1863839	C201830026	Spain		PRODUCT NAME: OZEMPIC-SEMAGLUTIDA; NATIONAL AUTHORISATION NUMBER: EU/1/17/1251; DATE OF AUTHORISATION: 20180208; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1251; DATE OF FIRST AUTHORISATION IN EEA: 20180208
1863839	300936	Netherlands		PRODUCT NAME: SEMAGLUTIDE; REGISTRATION NO/DATE: EU/1/17/1251 20180208
1863839	SPC/GB18/023	United Kingdom		PRODUCT NAME: SEMAGLUTIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/17/1251 (NI) 20180208; UK PLGB 04668/0331 20180208; UK PLGB 04668/0332 20180208; UK PLGB 04668/0333 20180208
1863839	18C1017	France		PRODUCT NAME: SEMAGLUTIDE; REGISTRATION NO/DATE: EU/1/17/1251 20180212
1863839	132018000000262	Italy		PRODUCT NAME: SEMAGLUTIDE(OZEMPIC); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1251, 20180212
1863839	122018000075	Germany		PRODUCT NAME: OZEMPIC-SEMAGLUTID; REGISTRATION NO/DATE: EU/1/17/1251 20180208

Market Dynamics and Financial Trajectory for WEGOVY

Last updated: March 25, 2026

What are the key market drivers influencing WEGOVY’s growth?

WEGOVY (semaglutide) is a once-weekly GLP-1 receptor agonist approved for Type 2 Diabetes and obesity. Its market growth stems from the rising global prevalence of these conditions, especially in developed economies. The World Health Organization estimates that over 400 million adults live with diabetes, with numbers projected to increase annually. Obesity affects more than 650 million adults worldwide, which further fuels demand for effective weight management treatments.

Key factors include:

• Increased diabetes prevalence: Accelerated by aging populations, urbanization, and sedentary lifestyles.
• Obesity epidemic: Growing recognition of obesity as a chronic disease increases patient and provider acceptance.
• Clinical efficacy and safety profile: WEGOVY demonstrates significant weight loss and glycemic control, which supports widespread adoption.

How does WEGOVY position relative to competitors?

WEGOVY competes within the GLP-1 receptor agonist class, dominated by products such as Novo Nordisk's Wegovy (semaglutide for obesity) and Ozempic (semaglutide for diabetes). Other competitors include Lilly’s Mounjaro (tirzepatide) and AstraZeneca's Bydureon (exenatide extended-release).

Product	Indications	Approval Date	Market share (2022 estimates)	Sales (2022)
Wegovy (semaglutide)	Obesity	June 2021 (FDA)	45%	$2.4 billion (estimated)
Ozempic (semaglutide)	Type 2 Diabetes	December 2017 (FDA)	30%	$3.1 billion (estimated)
Mounjaro (tirzepatide)	Diabetes, obesity	May 2022 (FDA)	15%	$0.5 billion (initial)

WEGOVY's differentiator is its robust weight-loss efficacy demonstrated in phase 3 trials, leading to rapid adoption in obesity management.

What are the regulatory and market access considerations?

The approval timeline influences market penetration. WEGOVY received FDA approval in June 2021 and European Commission approval in January 2022. Reimbursement policies significantly impact sales. In the US, Medicare and private insurers cover WEGOVY, but coverage varies across countries and healthcare systems, affecting sales trajectory.

Pricing has been set at approximately $1,349 per month in the US, aligning with competitors’ price points. Pricing strategies, discounts, and patient assistance programs influence net sales.

How do patents and regulatory filings affect future growth?

WEGOVY’s patent estate provides market exclusivity until at least 2030. Novo Nordisk filed for additional indications, including chronic weight management, which if approved, could expand revenue streams. Patent challenges from biosimilar manufacturers may threaten exclusivity beyond 2030, but current legal protections secure market dominance until then.

Regulatory filings in emerging markets (China, India, Brazil) are underway, expected to expand access and sales volume. However, regulatory approval timelines and pricing negotiations will influence revenue timing.

What is the long-term revenue outlook?

Projected sales growth estimates for WEGOVY hinge on:

• Market penetration expansion: Beyond the US and Europe into emerging markets.
• Indication expansion: Seeking approvals for long-term weight management and other metabolic disorders.
• Competitive threats: Launch of new molecules like Lilly’s Mounjaro, which shows comparable or superior efficacy in some trials.
• Pricing and reimbursement dynamics: Greater insurers’ coverage could support higher prices and sales volume.

Industry analysts estimate that WEGOVY could achieve peak sales between $8 billion and $12 billion globally by 2027, contingent on market access, regulatory approvals, and competitive landscape developments.

What are the risks impacting WEGOVY's financial trajectory?

• Regulatory delays or rejections: Could slow expansion or limit indications.
• Pricing pressure: From biosimilars or aggressive competitor pricing.
• Market saturation: In mature markets, growth may plateau as adoption rates stabilize.
• Legal challenges: Patent litigation could impact exclusivity periods.
• Global economic uncertainties: Affecting healthcare budgets and reimbursement policies.

Key Takeaways

• WEGOVY’s growth is driven by increasing prevalence of obesity and Type 2 diabetes.
• It faces competition from Wegovy (Novo Nordisk), Mounjaro (Lilly), and others.
• Regulatory approvals and reimbursement coverage are critical for expansion.
• Peak sales are projected between $8B and $12B by 2027.
• Risks include regulatory delays, market competition, and pricing pressures.

FAQs

1. What factors differentiate WEGOVY from other GLP-1 drugs?
Its dosing schedule (once weekly) and demonstrated superior weight-loss effects. Clinical trials show average weight loss of approximately 15% over 68 weeks, which surpasses competitors.

2. How does patent protection influence WEGOVY’s market exclusivity?
Patents expire around 2030, but supplementary protections, process patents, and regulatory data exclusivities sustain market advantage until then.

3. What emerging markets offer growth potential for WEGOVY?
China, India, and Brazil are key targets, with regulatory processes underway. These markets represent significant growth opportunities given their large populations and increasing disease burden.

4. How does the competition from Mounjaro impact WEGOVY?
Mounjaro (tirzepatide) shows comparable weight loss and glycemic control. Its dual mechanism offers a competitive alternative, potentially eroding WEGOVY’s market share if it demonstrates superior efficacy or lower price.

5. What is the impact of healthcare policy changes on WEGOVY’s sales?
Reimbursement policies influence patient access. Policies favoring metabolic disorder treatments improve sales, whereas tighter cost controls or exclusions reduce market penetration.

---

References

[1] World Health Organization. (2023). Diabetes Fact Sheet. https://www.who.int/health-topics/diabetes#tab=tab_1
[2] European Medicines Agency. (2022). WEGOVY approval details. https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy
[3] Novo Nordisk. (2022). WEGOVY product information. https://www.novonordisk.com
[4] IQVIA. (2022). Global GLP-1 receptor agonist market report.